Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Mavacamten is often referred to as “first-in-class” because it addresses the root cause of obstructions. Here’s everything you should know about its recent progress.
The 71st annual American College of Cardiology’s Scientific Session saw several wins over the weekend, led by some of the life sciences industries’ largest companies.
Oculis has identified pressing unmet therapeutic needs and innovative, differentiated approaches to meet those needs.
On March 31, Cambridge, Massachusetts-based Nuvalent announced that Anna Protopapas has been appointed as Chair of its Board of Directors.
After wrapping up March with a flurry of PDUFA dates, the U.S. Food and Drug Administration has a more leisurely calendar for the first three weeks of April, at least in terms of drug approvals.
Neurocrine has noticed some positive results of valbenazine for treating Huntington’s diseases related chorea. Here’s all about what they found in the study.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
The landmark Human Challenge Programme deliberately exposed 36 young and healthy participants ages 18 to 30 with no immunity to the SARS-CoV-2 virus for 14 days.
Dozens of life sciences companies are relocating to accommodate more employees and production capacities.
Job cuts in biotech tend to occur during the end of a quarter, and the end of this first quarter is no different. Continue reading for news of four biotech companies making workforce layoffs this week.
Ishtiaq Ali Saaem is sentenced to three years of probation following a guilty plea to charges he obstructed a federal investigation into his efforts to acquire the deadly toxin ricin.
The FDA requested additional data analyses from the pediatric studies that Merck stated it has submitted. The final decision is expected on July 1, 2022.
PRESS RELEASES
• Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs. • Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30. • The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.
